FDA Approves Zurzuvae (zuranolone) First Oral Treatment for Postpartum Depression
FDA Approves Balfaxar
FDA Approves Balfaxar (prothrombin complex concentrate, human-lans) for Warfarin Reversal
FDA Grants Full Approval for Blincyto (blinatumomab) to Treat Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
Conversion From Accelerated to Full Approval Reinforces Blincyto as Standard
FDA Approves New Class of Medicines to Treat Pediatric Type 2 Diabetes
June 20, 2023 — Today, the U.S. Food and Drug
FDA Approves Lynparza (olaparib) Plus Abiraterone and Prednisone or Prednisolone for Treatment of Adult Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Lynparza combination showed a clinically meaningful reduction in risk of
Farxiga Extended in the US to Reduce Risk of Cardiovascular Death and Hospitalisation for Heart Failure to a Broader Range of Patients
May 9, 2023 — AstraZeneca’s Farxiga (dapagliflozin) has been approved
FDA Approves Mydcombi
FDA Approves Mydcombi (tropicamide and phenylephrine hydrochloride) Ophthalmic Spray for
FDA Approves Rezzayo
FDA Approves Rezzayo (rezafungin for injection) for the Treatment of
FDA Approves Zavzpret
FDA Approves Zavzpret (zavegepant) Nasal Spray for the Acute Treatment
Centene Agrees to $215 Million Settlement With California for Alleged Medicaid Overbilling
Centene Corp. has agreed to pay more than $215 million